Table 2b.
Hazard Ratio (95% CI) for risk of incident cancer by p.C282Y/p.H63D status compared to those with no mutations in females
| Women | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||||||||||||
| No mutations | H63D+/− | H63D+/+ | C282Y+/H63D+ | C282Y+/− | C282Y +/+ | ||||||||||||||||
|
|
|||||||||||||||||||||
| Ref | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | ||||||
|
|
|||||||||||||||||||||
| Cancer (any, other than non-melanoma and liver cancer) | 1.00 | 1.01 | 0.98 | 1.04 | 0.54 | 0.98 | 0.90 | 1.07 | 0.70 | 0.95 | 0.87 | 1.04 | 0.23 | 0.99 | 0.95 | 1.04 | 0.79 | 0.92 | 0.78 | 1.08 | 0.31 |
| Bladder cancer | 1.00 | 0.90 | 0.74 | 1.08 | 0.26 | 0.98 | 0.60 | 1.62 | 0.94 | 1.41 | 0.93 | 2.14 | 0.11 | 0.92 | 0.72 | 1.17 | 0.51 | 1.65 | 0.82 | 3.32 | 0.16 |
| Blood cancer (any) | 1.00 | 0.98 | 0.89 | 1.08 | 0.68 | 1.07 | 0.82 | 1.40 | 0.60 | 0.67 | 0.48 | 0.93 | 0.02* | 1.03 | 0.90 | 1.17 | 0.70 | 1.03 | 0.63 | 1.69 | 0.91 |
| Leukemia | 1.00 | 1.09 | 0.91 | 1.30 | 0.34 | 1.42 | 0.92 | 2.18 | 0.11 | 0.83 | 0.48 | 1.45 | 0.51 | 1.16 | 0.93 | 1.46 | 0.19 | 0.88 | 0.33 | 2.37 | 0.80 |
| Lymphoma | 1.00 | 0.93 | 0.81 | 1.06 | 0.27 | 0.83 | 0.55 | 1.23 | 0.35 | 0.65 | 0.41 | 1.01 | 0.05 | 0.95 | 0.80 | 1.13 | 0.57 | 1.12 | 0.60 | 2.10 | 0.71 |
| Bone cancer | 1.00 | 0.93 | 0.84 | 1.02 | 0.11 | 0.76 | 0.57 | 1.02 | 0.06 | 1.14 | 0.90 | 1.44 | 0.28 | 1.00 | 0.88 | 1.12 | 0.94 | 1.09 | 0.70 | 1.69 | 0.71 |
| Brain cancer | 1.00 | 1.05 | 0.82 | 1.33 | 0.72 | 0.90 | 0.45 | 1.82 | 0.77 | 1.34 | 0.75 | 2.40 | 0.32 | 0.88 | 0.63 | 1.23 | 0.46 | 0.39 | 0.05 | 2.79 | 0.35 |
| Breast cancer | 1.00 | 1.04 | 0.99 | 1.09 | 0.16 | 1.09 | 0.96 | 1.25 | 0.19 | 0.99 | 0.87 | 1.14 | 0.93 | 0.97 | 0.91 | 1.04 | 0.36 | 0.90 | 0.69 | 1.18 | 0.45 |
| Colorectal cancer | 1.00 | 1.03 | 0.94 | 1.13 | 0.51 | 0.70 | 0.52 | 0.94 | 0.02* | 0.93 | 0.72 | 1.20 | 0.57 | 1.04 | 0.92 | 1.16 | 0.54 | 0.98 | 0.62 | 1.54 | 0.93 |
| Kidney cancer | 1.00 | 1.04 | 0.86 | 1.26 | 0.67 | 1.04 | 0.62 | 1.75 | 0.87 | 1.10 | 0.67 | 1.82 | 0.71 | 1.19 | 0.94 | 1.50 | 0.14 | 1.40 | 0.62 | 3.13 | 0.42 |
| Lung cancer | 1.00 | 1.02 | 0.92 | 1.12 | 0.72 | 1.04 | 0.80 | 1.36 | 0.75 | 1.00 | 0.77 | 1.31 | 0.97 | 0.99 | 0.87 | 1.12 | 0.85 | 1.12 | 0.71 | 1.77 | 0.62 |
| Melanoma | 1.00 | 0.98 | 0.87 | 1.10 | 0.77 | 0.88 | 0.63 | 1.24 | 0.46 | 0.81 | 0.57 | 1.15 | 0.23 | 0.97 | 0.83 | 1.13 | 0.67 | 0.89 | 0.48 | 1.66 | 0.71 |
| Oesophageal cancer | 1.00 | 1.08 | 0.85 | 1.36 | 0.53 | 0.88 | 0.43 | 1.77 | 0.71 | 0.54 | 0.22 | 1.30 | 0.17 | 0.96 | 0.70 | 1.32 | 0.80 | 0.35 | 0.05 | 2.52 | 0.30 |
| Ovarian cancer | 1.00 | 0.90 | 0.79 | 1.03 | 0.14 | 0.87 | 0.59 | 1.27 | 0.47 | 1.08 | 0.76 | 1.52 | 0.67 | 0.92 | 0.78 | 1.10 | 0.38 | 0.76 | 0.36 | 1.60 | 0.47 |
| Pancreatic cancer | 1.00 | 1.01 | 0.84 | 1.20 | 0.95 | 1.00 | 0.60 | 1.64 | 0.99 | 0.43 | 0.20 | 0.90 | 0.03* | 1.24 | 1.00 | 1.54 | 0.05 | 0.21 | 0.03 | 1.49 | 0.12 |
| Prostate cancer | 1.00 | N/A | |||||||||||||||||||
| Stomach cancer | 1.00 | 0.94 | 0.72 | 1.23 | 0.65 | 0.65 | 0.27 | 1.59 | 0.35 | 0.88 | 0.41 | 1.87 | 0.74 | 1.06 | 0.77 | 1.48 | 0.71 | 1.25 | 0.40 | 3.92 | 0.70 |
n=451,143 participants of European descent. Participants followed from baseline (2006-2010) via electronic medical records: Hospital impatient data (to March 2021) and cancer registries (to July 2019). Adjusted for age, assessment centre, genotype chip, and PC1-PC10. Excludes prevalent diagnoses at baseline.
*
p<0.05
**
p<0.003 (Bonferroni corrected p-value threshold)